New York group aims to speed recruitment with e-records

By Gareth Macdonald

- Last updated on GMT

Related tags: Clinical trial, Health care, Clinical research

A US group representing hospitals in New York wants to accelerate clinical research process by improving trial access to electronic patient records, while maintaining patient privacy.

The Partnership to Advance Clinical Electronic Research (PACeR), under the leadership of the Healthcare Association of New York State (HANYS), will examine ways of integrating electronic medical data into clinical research

A HANYS spokesman explained that: “The adoption of electronic medical records by health care providers has resulted in emerging databases of information that will be tremendously valuable to medical research.

PACeR’s ultimate goal is to link these data resources with clinical trials in a manner that greatly improves research and patient outcomes, while ensuring data and privacy protections.”

The ultimate aim is to develop online tools that notify a physician if a patient meets with the inclusion criteria of a particular study which, PACeR chair David Krusch, believes will improve on current “cumbersome” recruitment processes.

Krusch told the Wall Street Journal​ that: “Typically, trial operators would recruit patients from a hospital or medical center by hanging fliers in the cafeteria or in waiting rooms.

The PACeR group also believe that confidentiality will be maintained because only a patient’s physician will be notified of eligibility, at which point patient consent must still be obtained.

Pfizer, Quintiles

The PACeR scheme is funded by a number of leading US clinical research sites as well and Drug Administration (FDA), several data management companies and a number of representatives from the pharmaceutical sector.

Pfizer, Johnson & Johnson (J&J) and Merck & Co lead the list of drug companies that have signed up to the scheme with Quintiles being the foremost representative of the contract research sector to have joined the partnership.

The plan is to develop standard protocols that assess patients’ clinical trial eligibility in the next 12 months and roll out the scheme gradually over the next two years.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars